Latham & Watkins Advises Agenus on Formation of New Subsidiary

A life sciences focused team advises on formation of SaponiQX, building an innovative adjuvant platform and forming a collaboration with Ginkgo Bioworks.

September 14, 2021

Agenus Inc. (Agenus), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, has announced the launch of SaponiQx, a subsidiary of Agenus, dedicated to driving innovation in novel adjuvant discovery and vaccine design, and its partnership with Ginkgo Bioworks, Inc. (Ginkgo), the leading horizontal platform for cell programming. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), is enabling customers across industries to improve products and manufacturing processes, and to increase efficiency and sustainability, by making biology easier to engineer.

Latham & Watkins LLP represents Agenus Inc. in the transaction. The licensing team was led by partner Judith Hasko, with associates Jekkie Kim, Katie Mladinich, and Jiqiang Lin. The corporate deal team was led by partner Pete Handrinos, with associate Jasmine Joseph. Advice was also provided on tax matters by partners Kirt Switzer and Katharine Moir, with associate Alexander Farris.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.